Acetylshikonin from Zicao Prevents Obesity in Rats on a High-Fat Diet by Inhibiting Lipid Accumulation and Inducing Lipolysis

• Published in: PloS one 2016-01, Vol.11 (1), p.e0146884
• Main Authors: Su, Meiling, Huang, Wendong, Zhu, Banghao
• Format: Article
• Language: English
• Subjects: Adipocytes; Adipogenesis; Adipose tissue; Animals; Anthraquinones - pharmacology; Anthraquinones - therapeutic use; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Body weight; Care and treatment; Complications and side effects; Diabetes; Diet, High-Fat - adverse effects; Disease; Drug dosages; Drugs; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Efficiency; Fatty acids; Food; Glycerol; High fat diet; Lipase; Lipid Metabolism - drug effects; Lipids; Lipolysis; Lipolysis - drug effects; Liver; Male; Medicine; Metabolism; Obesity; Obesity - prevention & control; Patient outcomes; Pharmacology; Phosphorylation; Prevention; Protein kinase A; Proteins; Rats; Rats, Sprague-Dawley; Rodents; Traditional Chinese medicine; Transcription factors; Triglycerides; Weight control; Weight reduction
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0146884

Various drugs have been developed to treat obesity, but these have undesirable secondary effects, and an efficient but non-toxic anti-obesity drug from natural sources is desired. This study investigated the anti-obesity effects and mechanisms of action of acetylshikonin (AS)-which is used in traditional Chinese medicine-in rats on a high-fat diet (HFD). Rats were fed a normal diet or an HFD; the latter group was received no treatment or were treated with 100, 300, or 900 mg/kg AS extract by intragastric administration for 6 weeks. In addition, 3T3-L1 adipocytes were treated with AS and the effects on adipogenesis and lipolysis were evaluated by western blot analysis of adipogenic transcription factors and lipid-metabolizing enzyme levels and the phosphorylation status of protein kinase (PK) A and hormone-sensitive lipase (HSL). AS prevented HFD-induced obesity including reduction in body weight, white adipose tissue content, liver mass, and serum triglyceride and free fatty acid levels in rats. It also suppressed the expression of adipogenic differentiation transcription factors and decreased the expression of the adipocyte-specific proteins HSL and adipose triglyceride lipase (ATGL). Furthermore, AS treatment induced lipolysis, leading to the release of glycerol and increased in PKA and HSL phosphorylation. These findings demonstrate that AS has anti-obesity effects in a rat model and may be a safe treatment for obesity in humans.